TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The CDC’s updated 2026 antimicrobial resistance report identifies 19 pathogens with threat levels ranging from serious to urgent, plus six on a watch list. The agency estimates the pathogens collectively cause 9.7 million infections and 50,800 deaths in the United States each year; four drug-resistant pathogens are classified as urgent threats.
The CDC’s updated 2026 antimicrobial resistance report estimates that the pathogens it tracks cause 9.7 million infections and 50,800 deaths in the United States each year. The agency classifies 19 pathogens across serious, concerning and urgent threat levels, with four drug-resistant organisms at the top tier and six additional pathogens on a watch list.
The four pathogens on the CDC’s urgent threats list are Candida auris, carbapenem-resistant Acinetobacter, carbapenem-resistant Enterobacterales and drug-resistant Neisseria gonorrhoeae. The report says these infections are difficult to treat because resistance limits the medicines that can work against them. Some present particular risks in healthcare settings, where patients may be medically vulnerable or exposed to invasive devices and contaminated surfaces or equipment.
The report records substantial U.S. impacts for several organisms in 2023. Carbapenem-resistant Acinetobacter was linked to 9,497 hospitalizations and an estimated 817 deaths. Carbapenem-resistant Enterobacterales were linked to 14,878 hospitalizations and an estimated 1,252 deaths. The CDC also estimates that drug-resistant gonorrhea caused 787,000 infections that year; 55.4% of gonorrhea cases were resistant to at least one of six antibiotics or had elevated minimum inhibitory concentrations.
Other changes include drug-resistant Neisseria meningitidis entering the serious-threat category and drug-resistant dermatophytes, drug-resistant Haemophilus influenzae and nontuberculous mycobacteria joining the watch list. Clostridioides difficile moved from urgent to serious threat status. The report attributes the decline in its cases since 2011 in part to successful infection-prevention measures.
The Costs of Limited Treatment Options
Antimicrobial resistance can make infections harder to treat and may leave clinicians with fewer effective medicines. In a statement cited by MedPage Today, Wendy Armstrong, president of the Infectious Diseases Society of America, said resistant infections can prolong hospital stays and increase healthcare costs. She also warned they can complicate care such as cancer chemotherapy, organ transplants and surgery.
The report’s figures combine infections and deaths across the pathogens it tracks, rather than describing one outbreak or a single disease. The scale of the estimated annual burden matters for hospitals, public health agencies and patients who may need procedures or treatments that carry infection risks. The category changes also signal where the CDC sees a need for attention, while watch-list status reflects pathogens the agency is monitoring as their threat develops.
These estimates do not mean that every infection is fatal or that every listed pathogen poses the same risk to every person. The report describes population-level burden. Individual risk depends on the organism, the patient’s health and the circumstances of exposure.
Products Worth Considering
Withings Body Smart Wi-Fi and Bluetooth Body Composition Scale
Philips Sonicare 5950 Rechargeable Electric Toothbrush with 2 Brush Heads, Pink
Oral-B iO Series 9 Limited Rechargeable Electric Toothbrush with 7 Cleaning Modes
As an affiliate, we earn on qualifying purchases.
How the CDC Revised Its Threat List
The 2026 report updates the CDC’s assessment of antimicrobial-resistant pathogens in the United States. It groups 19 pathogens by threat level, from concerning or serious to urgent, and identifies six others as potential threats on a watch list. The classifications are meant to distinguish established public health concerns from organisms whose burden or risk is still being monitored.
One prominent change is C. difficile’s move from urgent to serious. The source report says infections have declined since 2011, with prevention efforts contributing to the change. In contrast, the CDC added several organisms to its watch list and raised drug-resistant N. meningitidis to serious status, reflecting changes in how the agency categorizes the threats.
The report also describes the rise in reported C. auris cases: from 48 in 2016, when it was first reported in the United States, to 4,523 in 2023. Those are reported case counts for the stated years, not a measure of the annual death toll across all listed pathogens.
“These numbers are alarming by any measure, but they are particularly sobering when infectious diseases physicians connect real patients with these statistics in their everyday experience.”
— Wendy Armstrong, president of the Infectious Diseases Society of America
What the Estimates Do Not Show
The report’s headline burden is an agency estimate covering multiple pathogens. The supplied report summary does not break down the total of 9.7 million infections and 50,800 deaths by each pathogen, nor does it provide the estimation methods or uncertainty ranges. The figures therefore should not be read as a count of deaths from the four urgent threats alone.
The six watch-list organisms are described as potential threats, and the source says their disease burden is uncertain. It is not clear from the supplied material how quickly their classifications could change or what specific surveillance findings would prompt a revised category. The report’s figures for individual pathogens also refer to different measures, including reported cases, estimated deaths and hospitalizations, so they are not directly interchangeable.
Funding and Surveillance Ahead
Armstrong called on Congress to pass the PASTEUR Act, which would establish a federal program to support development of antimicrobial drugs targeting high-priority pathogens and infections. According to the source report, versions of the bill remain stalled in congressional committees. No passage date or next legislative action was provided.
For now, the CDC’s revised categories give public health agencies and healthcare providers an updated reference for monitoring resistant infections and prevention needs. The report’s watch-list additions and shifts in threat levels will be relevant to future surveillance and assessments, but the supplied material does not set out a timetable for another update.
Key Questions
What does the CDC estimate about annual infections and deaths?
The CDC estimates that the pathogens covered by its 2026 report cause 9.7 million infections and 50,800 deaths in the United States each year. The supplied summary does not provide a breakdown of those totals by pathogen.
Which pathogens are on the urgent threats list?
The four named urgent threats are Candida auris, carbapenem-resistant Acinetobacter, carbapenem-resistant Enterobacterales and drug-resistant Neisseria gonorrhoeae.
Why did C. difficile move to a lower threat category?
The CDC moved Clostridioides difficile from urgent to serious threat status. The report summary says its case numbers have fallen since 2011, in part because of successful infection-prevention measures.
What is the CDC watch list?
The watch list names six pathogens viewed as potential threats. The supplied report summary says their disease burden is uncertain and does not specify when their status might change.
What is the status of the PASTEUR Act?
The Infectious Diseases Society of America’s president urged Congress to pass the bill, which would create a federal program to support antimicrobial drug development. The source report says versions of the legislation remain stalled in congressional committees.
Source: medpagetoday.com
